Alnylam et al resolve a fight over RNAi rights

The legal tussle over the rights to some key RNAi patents has been resolved. Some of the leading players in RNAi, including Alnylam, the Whitehead Institute for Biomedical Research, the University of Massachusetts and Germany's Max Planck Society, were headed for trial in Boston this month. But Xconomy notes that the warring parties agreed that Max Planck will take "the lead role in coordinating the prosecution of the Tuschl I and Tuschl II family of patents in the U.S." Story

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.